GENERALI, DANIELE
 Distribuzione geografica
Continente #
NA - Nord America 253
EU - Europa 208
AS - Asia 97
Continente sconosciuto - Info sul continente non disponibili 1
Totale 559
Nazione #
US - Stati Uniti d'America 238
IE - Irlanda 73
CN - Cina 45
UA - Ucraina 36
IT - Italia 32
GB - Regno Unito 16
CA - Canada 15
TR - Turchia 15
DE - Germania 14
FI - Finlandia 10
SE - Svezia 10
SG - Singapore 10
VN - Vietnam 10
BG - Bulgaria 6
HK - Hong Kong 6
KR - Corea 6
IN - India 4
BE - Belgio 3
FR - Francia 3
CZ - Repubblica Ceca 2
AL - Albania 1
CH - Svizzera 1
EU - Europa 1
PK - Pakistan 1
PL - Polonia 1
Totale 559
Città #
Dublin 73
Chandler 52
Jacksonville 31
Ann Arbor 21
Toronto 15
Dearborn 14
Milan 13
Beijing 9
Boston 7
Dong Ket 7
Lawrence 7
Modena 7
Mountain View 7
Boardman 6
Hong Kong 6
Izmir 6
Seoul 6
Singapore 6
Southend 6
Wilmington 6
Helsinki 5
Hefei 4
Houston 4
New York 4
Redmond 4
Ashburn 3
Brussels 3
Mumbai 3
Woodbridge 3
Paris 2
Sabbioneta 2
Seattle 2
Bovisio-Masciago 1
Brno 1
Changsha 1
Chengdu 1
Chongqing 1
Clearwater 1
Dongguan 1
Guangzhou 1
Islamabad 1
Jinan 1
Kunming 1
Los Angeles 1
Munich 1
Nanchang 1
Nanjing 1
Norwalk 1
Olomouc 1
Pune 1
Redwood City 1
San Giovanni Rotondo 1
Shaoxing 1
Taiyuan 1
Tappahannock 1
Tirana 1
Totale 368
Nome #
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer 124
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy" 81
Role of targeted agents in neuroendocrine tumours: results from a meta-analysis 79
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: a meta-regression of randomised prospective studies 75
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer 73
New omics information for clinical trial utility in the primary setting 70
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/HER2‐negative metastatic breast cancer: systematic review and meta‐analysis 66
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment 11
Phosphorylated ER alpha, HIF-1 alpha, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer 8
Totale 587
Categoria #
all - tutte 3.024
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.024


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202065 0 0 0 1 7 12 20 6 7 4 0 8
2020/202165 1 6 0 7 6 2 7 0 14 1 9 12
2021/202251 3 14 0 1 3 2 2 10 6 2 1 7
2022/2023195 10 4 7 17 16 14 1 15 94 1 9 7
2023/202491 8 3 4 0 5 13 8 12 1 0 21 16
2024/202517 3 2 12 0 0 0 0 0 0 0 0 0
Totale 587